We, therefore, speculate that the basis for manifestation as either TP53 aberrant AML or MDS as well as their different survival probabilities is mainly due to different co-mutational events occurring secondary to the TP53 aberration. The gene discussed is TP53; the disease is acute myeloid leukemia.